Supplementary information

Additional files:

**Figure S1.** A) Gating strategy and phenotype of E7-specific CD8⁺ T cells in blood. Representative data shown from mice vaccinated with $10^9$ IU Ad-R9F. B) Gating strategy of E7-specific CD8⁺ TRM cells in the liver. Representative data shown from mice vaccinated with $10^9$ IU Ad-R9F.

**Figure S2.** A) Phenotype of adoptively transferred CD8⁺ T cells. Expression of CD44 and CD62L on sorted effector and central-memory T cell subsets from Ly5.1 mice before adoptive transfer to recipient mice. B, C) Absolute number of CD45.1⁺CD8⁺CD69⁺ T cells and CD45.1⁺CD8⁺CD69⁺ T cells in liver per 50,000 transferred TEM or TCM cells. Transferred cells were isolated from Ad-R9F vaccinated mice and injected into TC-1 tumor bearing mice (B) or mice that were previously vaccinated with $10^8$ IU Ad-R9F (C).

**Figure S3.** Phenotype of CD8⁺ T cells isolated from tumors at day 20 after TC-1 tumor challenge. Mice were challenged with TC-1 tumor cells (subcutaneously in the flank) at day 50 after IV vaccination with $10^9$ IU Ad-R9F. Low dose CD8 depleting antibody (20 µg IP) or FTY720 (50 µg IP) was administered twice per week starting 4 days before tumor challenge.

**Figure S4.** Phenotype of skin CD8⁺ T cells at the location of subcutaneous TC1 tumors at day 20 after tumor challenge. Mice were challenged with TC-1 tumor cells (subcutaneously in the flank) at day 50 after IV vaccination with $10^9$ IU Ad-R9F. CXCR3 depleting antibody (200 µg IP) or FTY720 (50 µg IP) was administered twice per week starting 4 days before tumor challenge.

**Figure S5.** Infiltration of IV labelled CD8⁺ T cells in tumor, spleen and liver at day 20 after TC-1 tumor challenge. Mice were challenged with TC-1 tumor cells (subcutaneously in the flank) at day 50 after IV vaccination with $10^9$ IU Ad-R9F. CXCR3 depleting antibody (200 µg IP) was administered twice per week starting 4 days before tumor challenge. 3 minutes before sacrifice, mice were injected IV (retro-orbitally) with 3 µg CD8a APC (clone 53.6-7, BioLegend).